Key clinical point: Adjuvant capecitabine was extremely well tolerated in a real-world population of patients with early triple-negative breast cancer (TNBC) who had invasive residual disease at surgery after receiving neoadjuvant chemotherapy.
Major finding: The rate of treatment discontinuation due to adjuvant capecitabine-related toxicity was very low (10.4%). After a median follow-up of 15 months, the 2-year disease-free survival rate was 62.0%, and the 2- and 3-year overall survival rates were 84.0% and 76.2%, respectively.
Study details: Findings are from an observational, retrospective study including 270 patients with TNBC who had residual disease even after receiving neoadjuvant chemotherapy and were treated with adjuvant capecitabine.
Disclosures: This research was supported by Funds Ricerca Corrente 2023 from the Italian Ministry of Health. Some authors declared receiving research grants, personal fees, speaker fees, honoraria, or travel grants or having other ties with several sources.
Source: Di Lisa FS et al. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: Real-world evidence from CaRe, a multicentric, observational study. Front Oncol. 2023;13:1152123 (May 16). doi: 10.3389/fonc.2023.1152123